Pennsaid

Contusions, Pain, Photophobia + 54 more
Treatment
10 FDA approvals
20 Active Studies for Pennsaid

What is Pennsaid

DiclofenacThe Generic name of this drug
Treatment SummaryDiclofenac is an anti-inflammatory medication used to treat pain and inflammation. It is a non-steroidal drug that works by blocking the production of certain enzymes responsible for causing inflammation and pain. Diclofenac is usually prescribed as first line treatment for acute and chronic pain and inflammation. It can be taken alone or in combination with other drugs to prevent ulcers caused by long-term use. Diclofenac was first approved by the FDA in 1988 and is sold under the brand name Voltaren.
Voltarenis the brand name
image of different drug pills on a surface
Pennsaid Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Voltaren
Diclofenac
1988
767

Approved as Treatment by the FDA

Diclofenac, also called Voltaren, is approved by the FDA for 10 uses including Chronic Pain and Pain .
Chronic Pain
Helps manage Pain
Pain
Helps manage Pain
Osteoarthritis of the Knee
Used to treat Osteoarthritis of the Knee in combination with Capsaicin
Osteoarthritis
Used to treat Osteoarthritis (OA) in combination with Misoprostol
Postoperative Inflammatory Response
Osteoarthritis of the Knee
Used to treat Osteoarthritis of the Knee in combination with Capsaicin
Stomach Ulcer
Used to treat develop NSAID-induced gastric ulcers in combination with Misoprostol
Osteoarthritis (OA)
Used to treat Osteoarthritis (OA) in combination with Misoprostol
Rheumatoid Arthritis
Cataract Surgery

Effectiveness

How Pennsaid Affects PatientsDiclofenac helps to reduce inflammation which in turn reduces pain and fever. However, it can increase the risk of getting an ulcer in the stomach because it reduces the protective mucus that is produced there.
How Pennsaid works in the bodyDiclofenac works by stopping the production of molecules called prostaglandins. Prostaglandins increase nerve firing, causing both pain and inflammation. Diclofenac blocks the receptors for these molecules, reducing their effect. It also reduces the body's ability to create a fever, by blocking the receptors that cause heat-generation and heat-loss in the hypothalamus. Finally, it stops T-helper cells from activating and differentiating, which is believed to play a role in arthritis.

When to interrupt dosage

The advised dosage of Pennsaid is contingent upon the diagnosed affliction, including Joint Pain, Postoperative Inflammatory Response and Osteoarthritis (OA). The portion of dosage is contingent upon the technique of delivery (e.g. Cream; Kit; Solution or Kit; Oil; Solution / drops) illustrated in the following table.
Condition
Dosage
Administration
Catarrh
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Inflammation
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Fever
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Postoperative
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Acute Coryza
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Chronic Pain
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Rheumatoid Arthritis
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Pain
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Photophobia
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Muscle Pain
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Radiculopathy
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Pain
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Arthritis, Gouty
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
corneal refractive surgery
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Rheumatism
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Postoperative Pain
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Seasonal Allergic Conjunctivitis
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Pain
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Inflammation
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical
Acute Coryza
100.0 mg, , 1.0 mg/mL, 50.0 mg, 75.0 mg, 16.05 mg/mL, 3.5 mg/mL, 25.0 mg, 0.01 mg/mg, 180.0 mg, 0.018 mg/mg, 1.0 mg/mg, 0.1 %, 1.5 %, 30.0 mg/mL, 0.03 mg/mg, 2.32 %, 1.16 %, 37.5 mg/mL, 0.02 mg/mg, 18.0 mg, 35.0 mg, 0.3 mg/mg, 10.0 mg, 1000.0 mg, 10.0 mg/mL, 12.5 mg, 0.015 mg/mg, 100.0 mg/mL, 3.0 mg/mg, 5.7 mg/mg, 13.0 mg, 0.013 mg, 0.001 mg/mg
, Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Ophthalmic, Solution, Solution - Ophthalmic, Tablet, delayed release, Tablet, delayed release - Oral, Topical, Solution - Topical, Tablet, Tablet - Oral, Powder, for solution, Powder, for solution - Oral, Solution / drops, Solution / drops - Ophthalmic, Tablet, film coated, Tablet, film coated - Oral, Liquid, Liquid - Topical, Gel, Gel - Topical, Tablet, extended release, Tablet, extended release - Oral, Patch, Patch - Topical, Capsule, liquid filled, Capsule, liquid filled - Oral, Rectal, Suppository, Suppository - Rectal, Liquid - Ophthalmic, Kit, Aerosol, metered - Topical, Aerosol, metered, Kit - Topical, Tablet, sugar coated, Tablet, sugar coated - Oral, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, Capsule - Oral, Cream, Cream - Topical, Powder - Oral, Transdermal, Solution / drops - Transdermal, Oral; Topical, Kit - Oral; Topical, Sublingual, Tablet, coated, Tablet, coated - Oral, Drug delivery system, Drug delivery system - Topical

Warnings

Pennsaid has twenty-nine contraindications, so it must not be taken when encountering any of the conditions mentioned in the following table.Pennsaid Contraindications
Condition
Risk Level
Notes
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
Heart failure
Do Not Combine
Crohn's Disease
Do Not Combine
recent history of anal bleeding
Do Not Combine
Hemorrhagic Disorders
Do Not Combine
Gastritis
Do Not Combine
inflammatory lesions of the Rectum
Do Not Combine
active Gastrointestinal Bleeding
Do Not Combine
Pulse Frequency
Do Not Combine
Pulse Frequency
Do Not Combine
active Gastrointestinal Perforation
Do Not Combine
Duodenal Ulcer
Do Not Combine
Coronary Artery Bypass Grafting
Do Not Combine
Severe Hepatic Impairment
Do Not Combine
Ulcerative Colitis
Do Not Combine
Liver Diseases
Do Not Combine
Stroke
Do Not Combine
Third trimester of pregnancy
Do Not Combine
Hematochezia
Do Not Combine
Kidney Failure
Do Not Combine
Kidney Failure
Do Not Combine
Anus
Do Not Combine
Ulcer
Do Not Combine
damaged skin
Do Not Combine
Gastric ulcer
Do Not Combine
Peptic Ulcer
Do Not Combine
Hyperkalemia
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Diclofenac may interact with Pulse Frequency
There are 20 known major drug interactions with Pennsaid.
Common Pennsaid Drug Interactions
Drug Name
Risk Level
Description
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Diclofenac.
Cabazitaxel
Major
The metabolism of Cabazitaxel can be decreased when combined with Diclofenac.
Cyclophosphamide
Major
The metabolism of Cyclophosphamide can be decreased when combined with Diclofenac.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Diclofenac.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Diclofenac.
Pennsaid Toxicity & Overdose RiskAn overdose of Voltaren may cause symptoms such as fatigue, drowsiness, nausea, vomiting, and stomach pain. In rare cases, high blood pressure, kidney failure, difficulty breathing, or coma may occur. If a Voltaren overdose occurs, supportive care should be provided and vomiting may be induced and activated charcoal administered if the overdose occurred within the last 4 hours.
image of a doctor in a lab doing drug, clinical research

Pennsaid Novel Uses: Which Conditions Have a Clinical Trial Featuring Pennsaid?

At present, 491 active trials are being conducted to investigate the potential of Pennsaid for alleviating Inflammation, Argon Laser Trabeculoplasty and Osteoarthritis of the Knee.
Condition
Clinical Trials
Trial Phases
Chronic Pain
129 Actively Recruiting
Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1
Osteoarthritis of the Knee
82 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
Inflammation
58 Actively Recruiting
Not Applicable, Early Phase 1, Phase 1, Phase 2, Phase 3, Phase 4
Rheumatoid Arthritis
54 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1
Postoperative Pain
18 Actively Recruiting
Phase 4, Phase 2, Phase 1, Phase 3, Not Applicable
Dysmenorrhea
1 Actively Recruiting
Not Applicable
Muscle Pain
3 Actively Recruiting
Phase 4, Not Applicable, Phase 2
Conjunctivitis
0 Actively Recruiting
Musculoskeletal System
1 Actively Recruiting
Not Applicable
corneal refractive surgery
0 Actively Recruiting
Postoperative Inflammatory Response
0 Actively Recruiting
Photophobia
2 Actively Recruiting
Not Applicable
Pain
3 Actively Recruiting
Not Applicable
Stomach Ulcer
0 Actively Recruiting
Rheumatism
0 Actively Recruiting
Juvenile arthritis
8 Actively Recruiting
Phase 2, Not Applicable, Phase 3
radial keratotomy
0 Actively Recruiting
Joints
0 Actively Recruiting
Pericarditis
1 Actively Recruiting
Phase 2, Phase 3
Acute Coryza
0 Actively Recruiting

Pennsaid Reviews: What are patients saying about Pennsaid?

5Patient Review
3/14/2018
Pennsaid for Osteoarthritis of the Knee
I started seeing results after just two weeks of use. The swelling in my right knee went down and I could bear weight on it again. This is a great treatment that I would definitely recommend to others.
5Patient Review
6/18/2018
Pennsaid for Osteoarthritis of the Knee
I don't usually leave reviews, but I felt compelled to in this case. This treatment has given me more relief than anything else I've tried for my painful knees. I can now walk down stairs normally instead of having to take each step one at a time. It might not work for everyone, but it's definitely worth a shot!
4.7Patient Review
4/5/2017
Pennsaid for Joint Damage causing Pain and Loss of Function
I found relief for my aching wrists by applying this treatment from my wrist to the end of my thumbs on both hands. I noticed that after about half an hour, it was necessary to wash off the medication and apply eucerin cream to avoid redness and peeling.
2.7Patient Review
8/30/2021
Pennsaid for Osteoarthritis of the Knee
While this treatment may improve quality of life for some, I found the results to be hardly noticeable. If not for insurance, I wouldn't continue using it given the price point.
2.3Patient Review
4/19/2017
Pennsaid for Osteoarthritis of the Knee
I have chrondromalsia in both my knees and this medication did nothing to help, despite applying it three times a day. No side effects or relief. Bengay works better. Don't waste your money on this one.
2Patient Review
6/28/2016
Pennsaid for Joint Damage causing Pain and Loss of Function
I was given a sample of this med for severe joint pain on my knuckles. I have only one hand due to an accident and its difficult to use. i need to use a sponge, it takes a lot of pain away for a while, after use when it dries i wash my hand, does it take the med away what danger does the med have if i dont wash
1.7Patient Review
4/28/2017
Pennsaid for Osteoarthritis of the Knee
Dr prescribed for knee, worked ok once. Second use the side effects were so horrible (please research) that it left me in pain for weeks. First my knee appeared to have a bad sunburn then it through the process of flaking and peeling off skin. it has been about a month later and I am still itchy all over and still have a red scar covering my knee like a birthmark. The itching has spread all over my body.
1.7Patient Review
2/14/2018
Pennsaid for Joint Damage causing Pain and Loss of Function
As someone who has had a torn meniscus and bruised tibia, I can say that this medication did not help me at all. In fact, the only times it appeared to work were when I was taking other medications as well.
1.7Patient Review
12/30/2018
Pennsaid for Joint Damage causing Pain and Loss of Function
I would highly recommend "testing" this product before using it on a larger area of your body. I applied the product to my knee and got an awful rash that lasted for five weeks. It was incredibly painful, itchy, and swollen. I also broke out in hives all over my body which have now been present for four weeks. Needless to say, I will not be using this product again.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about pennsaid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Pennsaid?

"or

skin irritation (e.g., dryness, redness, stinging, itching, scaling, hives, swelling), drowsiness, dizziness, nausea, stomach pain, upset stomach, indigestion, or diarrhea."

Answered by AI

What is Pennsaid used to treat?

"Pennsaid is a nonsteroidal anti-inflammatory drug that is applied to the skin. It is used to treat the pain of osteoarthritis of the knee."

Answered by AI

Is Pennsaid same as Voltaren?

"Are Voltaren Gel and Pennsaid the Same Thing? Voltaren Gel and Pennsaid are both topical gel NSAIDs used to treat osteoarthritis pain in the joints, such as the hands and knees."

Answered by AI

How long does it take Pennsaid to start working?

"The full effect of this drug may not be felt for up to two weeks of regular use for certain conditions, like arthritis. If you're only using the drug as needed, keep in mind that pain medications are most effective when taken at the first sign of pain."

Answered by AI

Clinical Trials for Pennsaid

Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Image of University of California, San Francisco in San Francisco, United States.

Vision Centers for Eye Care

Any Age
All Sexes
San Francisco, CA
The goal of this clinical trial is to evaluate the effect of vision centers on access to eye care and eye health outcomes in South Asia. The main questions it aims to answer are: 1. Do vision centers increase visits to eyecare centers? 2. Do vision centers increase spectacle ownership and wearing? 3. Do vision centers improve visual acuity of the population? Researchers will compare outcomes in communities randomized to have a vision center is established with communities randomized to delay establishment of a vision center. Outcomes will be assessed through population-based surveys at baseline and after two years as well as through hospital records collected throughout the study period.
Waitlist Available
Has No Placebo
University of California, San FranciscoKieran O'Brien, PhD, MPH
Have you considered Pennsaid clinical trials? We made a collection of clinical trials featuring Pennsaid, we think they might fit your search criteria.Go to Trials
Image of Vanderbilt University Medical Center in Nashville, United States.

Lidocaine Infusions for Postoperative Pain

18+
All Sexes
Nashville, TN
The goal of this single-center, pragmatic, randomized, blinded, placebo-controlled trial is to evaluate the impact of intravenous (IV) lidocaine within the existing Enhanced Recovery After Surgery (ERAS)program on outcomes in patients after major abdominal surgery. The main questions the trial aims to answer are: The primary hypothesis is that utilization of IV lidocaine as part of a perioperative multimodal pain regimen will result in a reduction in hospital Case Mix Index-Adjusted Resource Length of Stay (CARLOS). The secondary hypotheses are that lidocaine infusion will result in a reduction in total inpatient opioid consumption (oral morphine milligram equivalents, oMMEs) and pain scores, and improved surgical outcomes (including return of bowel function, ileus, nausea, rapid responses called, surgical site infections, and ICU transfers), while also having minimal incidence of side effects (including double/blurry vision, tinnitus, sedation, and adverse events requiring early cessation).
Phase 4
Waitlist Available
Vanderbilt University Medical CenterDanial Shams, MD
Have you considered Pennsaid clinical trials? We made a collection of clinical trials featuring Pennsaid, we think they might fit your search criteria.Go to Trials
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.
Waitlist Available
Has No Placebo
Humana Healthcare Research, Inc. (+1 Sites)
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Have you considered Pennsaid clinical trials? We made a collection of clinical trials featuring Pennsaid, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security